Pfizer Inc. (NYSE:PFE) Shares Acquired by Mizuho Securities USA LLC

Mizuho Securities USA LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 46.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 537,102 shares of the biopharmaceutical company's stock after buying an additional 169,647 shares during the quarter. Mizuho Securities USA LLC's holdings in Pfizer were worth $14,249,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in PFE. Nordea Investment Management AB raised its stake in shares of Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock valued at $108,002,000 after acquiring an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI grew its holdings in Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after purchasing an additional 159,984 shares during the last quarter. NFJ Investment Group LLC raised its position in Pfizer by 12.8% in the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company's stock worth $11,129,000 after purchasing an additional 43,719 shares during the period. Daiwa Securities Group Inc. lifted its stake in Pfizer by 25.9% in the third quarter. Daiwa Securities Group Inc. now owns 804,522 shares of the biopharmaceutical company's stock worth $23,283,000 after purchasing an additional 165,611 shares during the last quarter. Finally, Copley Financial Group Inc. purchased a new position in shares of Pfizer during the third quarter valued at approximately $577,000. Institutional investors own 68.36% of the company's stock.

Remove Ads

Pfizer Stock Down 2.2 %

Pfizer stock traded down $0.58 during midday trading on Tuesday, reaching $25.56. The company's stock had a trading volume of 47,484,282 shares, compared to its average volume of 36,645,983. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $144.96 billion, a P/E ratio of 18.13, a PEG ratio of 0.64 and a beta of 0.61. The stock's 50-day simple moving average is $26.15 and its 200-day simple moving average is $27.02. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the firm posted $0.10 EPS. Pfizer's revenue was up 24.7% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group decreased their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.